Primary PCI versus pharmacoinvasive strategy for ST elevation myocardial infarction

Area of Science:

• Cardiology
• Interventional Cardiology
• Emergency Medicine

Background:

• Persistent reduced flow in the infarct-related artery is common in acute myocardial infarction.
• Pharmacoinvasive strategy aims to improve reperfusion and patient outcomes.
• This study compares pharmacoinvasive strategy with primary PCI and ischemia-driven PCI.

Purpose of the Study:

• To assess the safety and efficacy of a pharmacoinvasive strategy using streptokinase.
• To compare this strategy against primary PCI and ischemia-driven PCI.
• To evaluate the impact on myocardial salvage and clinical outcomes.

Main Methods:

• Sixty patients with acute STEMI within 12 hours were randomized into four groups.
• Groups included primary PCI, transfer PCI, pharmacoinvasive (streptokinase then PCI), and fibrinolysis with ischemia-driven PCI.
• Primary endpoint: infarction size and microvascular obstruction (MVO) assessed by cardiac MRI (CMR) 3-5 days post-MI.

Main Results:

• Pharmacoinvasive strategy significantly reduced infarction size, MVO, and major adverse cardiac and cerebrovascular events (MACCE) compared to fibrinolysis with ischemia-driven PCI.
• Minor bleeding events were significantly higher in the pharmacoinvasive group compared to other groups.
• Effective reperfusion and smaller infarct size were observed in STEMI patients unable to undergo primary PCI within 2 hours.

Conclusions:

• Pharmacoinvasive strategy is effective for reperfusion and reduces infarct size in early STEMI when primary PCI is not feasible within the optimal timeframe.
• This strategy provides a broader time window for PCI.
• A slightly increased risk of minor bleeding is associated with the pharmacoinvasive approach.